Development of CER-001: Preclinical Dose Selection Through to Phase I Clinical Findings by Constance H. Keyserling et al.
ORIGINAL RESEARCH ARTICLE
Development of CER-001: Preclinical Dose Selection Through
to Phase I Clinical Findings
Constance H. Keyserling1 • Ronald Barbaras1 • Renee Benghozi1 • Jean-Louis Dasseux1
 The Author(s) 2017. This article is published with open access at Springerlink.com
Abstract
Background CER-001 comprises recombinant human
apolipoprotein A-I complexed with phospholipids that
mimics natural, nascent, pre-b high-density lipoprotein
(HDL). We present animal model data showing dose-de-
pendent increases in cholesterol efflux with CER-001 and
its subsequent elimination by reverse lipid transport,
together with inhibition of atherosclerotic plaque progres-
sion. We report the first phase I study results with CER-001
in humans, starting at 0.25 mg/kg, which is 1/80th of the
safe dose (20 mg/kg) established in 4-week multiple-dose
animal studies dosed every second day.
Methods Healthy volunteers, 18–55 years old with a low-
density lipoprotein-cholesterol:HDL-cholesterol ratio
greater than 3.0, received single intravenous escalating
doses of CER-001 (0.25–45.0 mg/kg) and placebo in a
double-blind randomised cross-over fashion. Subjects were
followed up for 3 weeks post-dose. Assessments included
adverse event monitoring, blood sampling, and clinical
laboratory measurements.
Results Thirty-two subjects were enrolled. All CER-001
doses (0.25–45 mg/kg) were safe and well tolerated, with
an adverse event profile similar to placebo. Effects on
clinical chemistry, haematology and coagulation parame-
ters were comparable to placebo. No adverse effects of
CER-001 on electrocardiograms were observed. No
antibodies to apolipoprotein A-I were detected following
single-dose administration of CER-001. Plasma
apolipoprotein A-I levels increased in a dose-related
manner and returned to baseline by 24 h post-dose for
doses up to 10 mg/kg but remained in circulation for[72 h
post-dose for doses [10 mg/kg. CER-001 caused eleva-
tions in plasma cholesterol and total and unesterified
cholesterol in the HDL fraction. Mobilisation of unesteri-
fied cholesterol in the HDL fraction was seen with CER-
001 at doses as low as 2 mg/kg.
Conclusion CER-001 is well tolerated when administered
to humans as single doses up to 45 mg/kg and mobilises
and eliminates cholesterol via reverse lipid transport.
Key Points
CER-001 is well tolerated when administered to
humans as single doses up to 45 mg/kg.
CER-001 mobilises cholesterol and increases its
elimination via reverse lipid transport.
CER-001 inhibits atherosclerotic plaque progression,
providing considerable optimism that it may address
the residual risk of cardiovascular events that
remains after maximum clinical benefit has been
achieved using low-density lipoprotein-cholesterol-
lowering therapies.
1 Introduction
CER-001 is a negatively charged, engineered, pre-b high-
density lipoprotein (HDL) particle that contains the natural
HDL protein, human recombinant apolipoprotein A-I
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(ApoA-I) together with natural phospholipids, combined
into a single small discoidal particle. As such, CER-001
mimics the structure, the charge and function of nascent
HDL. The phospholipid species used in CER-001 were
selected for their ability to form a discoidal complex with a
strong affinity for cholesterol [1, 2], a negative charge to
slow clearance by the kidney [3] and to trigger recognition
by the liver [4], together with the high stability of the
complexes in the circulation.
CER-001 possesses all the structural and functional
biological properties of nascent HDL, including the ability
to penetrate atherosclerotic plaque, to collect cholesterol,
transport it from the plaque and then be recognised by HDL
receptors in the liver where cholesterol is eliminated. In
low-density lipoprotein (LDL)-deficient mice fed a high-
cholesterol diet, CER-001 has been shown to stimulate
reverse lipid transport and atherosclerosis regression [5]. In
a recent study using radiolabelled CER-001, Zheng and co-
workers [6] demonstrated that CER-001 enhances plasma
cholesterol efflux capacity and accesses advanced
atherosclerotic plaques in patients with atherosclerotic
carotid artery disease.
CER-001 is an intravenous therapy currently in devel-
opment for the secondary prevention of cardiovascular
events after an acute coronary syndrome [7, 8], familial
hypercholesterolaemia [9] and for rare severe genetic
deficiencies in HDL particle synthesis/maturation (familial
primary hypoalphalipoproteinaemia) [10], for which two
separate orphan designations have been granted by the
European Medicines Agency, specifically apolipoprotein
A-I (ApoA-I) deficiency and ATP-binding cassette trans-
porter 1 (ABCA1) deficiency.
While clinical evidence on the effectiveness of CER-001
and similar therapies continues to increase, very limited
data are available showing the key information used in the
dose selection process. Here, we present key in vitro/
in vivo findings and steps in the development of CER-001,
focusing specifically on dose selection data, together with
the first phase I clinical study results with the product in
humans.
2 Methods
2.1 Key Preclinical Pharmacology Studies
2.1.1 Cholesterol Mobilisation
In a fasted New Zealand White rabbit, cholesterol mobil-
isation model, CER-001 or phosphate/sucrose buffered
saline vehicle control was infused intravenously at a rate of
1 mL/min into fasted animals in an infusion volume of
5 mL/kg; the final doses of CER-001 were 2.5, 5, 10 and
20 mg/kg, with three animals per dose group. Venous
blood was collected via a permanent catheter that was
placed the day before the experiment in the marginal vein
of the ear and reached the jugular vein lumen. Blood
samples were collected at baseline, then at 12 min (end of
infusion), 30 min, 45 min, 1, 2, 4, 6, 8, 30 and 34 h after
initiating the infusion. Plasma lipoprotein levels were
determined by high-performance liquid chromatography
(HPLC) size exclusion fractionation with inline unesteri-
fied and total cholesterol detection (see Online Supple-
mentary Material) [11]. The area under each of the main
HPLC peaks corresponding to lipoproteins with the sizes of
very low-density lipoprotein (VLDL), LDL and HDL was
integrated. The percent of the total unesterified and total
cholesterol area in each lipoprotein fraction was multiplied
by the total plasma cholesterol or unesterified cholesterol to
determine the level of cholesterol in each lipoprotein
fraction. Cholesterol ester levels in each fraction were
determined by subtracting the unesterified cholesterol from
the total cholesterol in each fraction. In this model,
increases in plasma or HDL-cholesterol levels are indica-
tive of tissue cholesterol mobilisation by HDL. Data are
presented as mean values of each timepoint in each treat-
ment group; results at each timepoint are also expressed as
the change from baseline by subtracting the baseline value
from the value at that particular timepoint.
2.1.2 Attenuated Inhibition of Atherosclerotic Plaque
Progression
There is evidence in the literature for a trend towards
decreased efficacy with higher doses of different HDL
mimetics (i.e. ETC-216, CER-001) in clinical trials
[7, 12]. The dose–response effect of CER-001 and HDL3
was assessed in vivo on plaque formation in the ligatured
carotids of apolipoprotein E (ApoE)-/- mice fed a high-
cholesterol diet. The left carotid was ligated in anaes-
thetised ApoE-/- mice and groups of mice (n = 12) were
subsequently fed with a high-cholesterol diet and treated
(retro-orbital injection) every second day with different
dose levels of CER-001 (2–50 mg/kg) or HDL3
(5–50 mg/kg) for 2 weeks. After eight infusions, mice
were anaesthetised [intraperitoneal injection of a mixture
of ketamine (100 mg/kg) and xylazine (10 mg/kg)] and
the carotids were excised and stored at -80 C until
analysed. For each group, the lipids were extracted from
each excised carotid and the cholesterol level determined
by HPLC (see Online Supplementary Material). Data are
presented as mean (±standard error of the mean) values of
each treatment group by dose and compared with the
control group.
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2.2 Phase I Single Rising-Dose Clinical Study
This was a randomised, double-blind, placebo-controlled,
cross-over, single rising-dose study design in healthy male
and female volunteers, 18–55 years of age, with an LDL-
cholesterol:HDL-cholesterol ratio[3.0. The objectives of
the study were to assess the safety, tolerability, pharma-
cokinetics and pharmacodynamics of CER-001 when
administered as a single intravenous dose in healthy dys-
lipidaemic volunteers.
Subjects were treated in four cohorts of eight, with each
subject receiving a single dose of CER-001 and a single
dose of placebo in a randomised cross-over fashion.
Escalating doses of 0.25, 0.75, 2.0, 5.0, 10.0, 15.0, 30.0 and
45.0 mg/kg were studied. Study medication was infused
intravenously over 1 h for doses up to 30 mg/kg and over
2 h for doses of 45 mg/kg. The eight subjects included at
each dose level were treated as follows: two subjects (one
active/one placebo) were dosed on the first day; after 24 h,
two additional subjects (one active/one placebo) were
dosed; and after an additional 24 h, the remaining four
subjects in the cohort (two active/two placebo) were dosed.
During each study period, subjects remained in the clinic
for 72 h following dose administration on day 1 and then
returned to the clinic for outpatient follow-up visits on days
8, 15 and 22. Dose escalation for each dose level above
0.25 mg/kg was made after careful review of all available
safety, tolerance and pharmacokinetic/pharmacodynamic
data for previous doses and in consultation with the
investigator.
Study assessments included adverse event (AE) moni-
toring, routine clinical chemistry, haematology and coag-
ulation measurements, electrocardiograms, physical
examination and monitoring of vital signs. For the phar-
macokinetic assessment, clinical chemistry, ApoA-I levels
were measured using an automated turbidimetric
immunoassay method (Pentra 400 autoanalyzer, manufac-
tured by Horiba ABX SAS, Montpellier, France). Phar-
macodynamic effect was determined by serial
determinations of lipoprotein profiles (LDL, HDL and
VLDL fractions) in total and unesterified cholesterol using
a validated HPLC method.
3 Results
3.1 Key Preclinical Pharmacology Studies
3.1.1 Cholesterol Mobilisation
In this rabbit cholesterol mobilisation model, intravenous
administration of CER-001 at doses of 2.5, 5, 10 and
20 mg/kg increased plasma phospholipids and ApoA-I, and
mobilised cholesterol in a dose-dependent manner, with
effects being observed at the 2.5-mg/kg dose (Fig. 1). The
majority of the cholesterol increase was in the form of
unesterified cholesterol (Fig. 1b), although a CER-001-
dependent increase in plasma cholesterol ester was
observed (Fig. 1c). Plasma phospholipids and cholesterol
returned to baseline levels within 30–34 h of treatment
initiation (Table 1) [animals had free access to food 8 h
after administration of CER-001]. The presence of human
ApoA-I in the HDL fraction after HPLC fractionation
suggests that the cholesterol-loaded CER-001 complexes
remain stable (i.e. in the range of the HDL size) throughout
the cholesterol mobilisation process in rabbits. It is worth
noting that similar dose-dependent increases in cholesterol
mobilisation were also observed in rat and primate models
(data not shown).
3.1.2 Attenuated Inhibition of Atherosclerotic Plaque
Progression
We observed a gradually greater decrease for unesterified
and total cholesterol content in ligatured carotids as the dose
of CER-001 or HDL3 increased from 2 to 5 to 10 mg/kg
(Fig. 2a, b). For CER-001 dose levels above 10 mg/kg, the
cholesterol content did not decrease butwas at the same level
as that of untreated mice (i.e. a U-shaped dose–response
curve was observed). The ABCA1 protein content in the
ligatured carotids paralleled that of the cholesterol content in
a similar dose-related manner (Fig. 2c). We observed that at
doses for which plaque formation in carotid (5 mg/kg of
CER-001 and HDL3) is maximally inhibited, carotid artery
ABCA1 protein levels are similar to those of untreated ani-
mals. In contrast, at the 50-mg/kg dose ofCER-001 orHDL3,
the carotid cholesterol content of plaque burden is similar to
that of untreated animals, and the carotid artery ABCA1
protein level is decreased by half compared with untreated
animals. Thus, down-regulation of macrophage ABCA1
induced by elevated concentrations of CER-001 or HDL3
appears to have attenuated the efficacy of the infused HDL to
inhibit plaque formation in the ApoE-/- mouse ligatured
carotid model. However, at the lower doses, increasing the
dose of CER-001 and HDL3 up to that observed threshold
slowed progression of carotid plaque while maintaining
normal levels of ABCA1 expression.
3.2 Phase I Single Rising-Dose Clinical Study
The study enrolled 32 subjects and evaluated CER-001 at
doses of 0.25–45 mg/kg. Thirty-one (97%) subjects com-
pleted the study. One subject was lost to follow-up after
period 2 day 14 (subject did not return for the day 22 end-
of-study visit and was not reachable at the telephone
number provided; this subject did not experience any AEs
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during the trial). Baseline characteristics were similar
across cohorts and dosing sequences (Table 2). Subjects
were predominantly male (94%), Caucasian (88%), had a
mean age of 34 years and a mean body mass index of
28 kg/m2. Mean baseline LDL-cholesterol was 136 mg/dL,
mean HDL-cholesterol was 36 mg/dL and the mean
LDL:HDL ratio was 3.9. Subjects had no chronic health
problems and were not taking any concomitant therapies.
Plasma levels of ApoA-I and sphingomyelin increased
in a dose-related manner. ApoA-I levels returned to base-
line by 24 h post-dose for doses up to 10 mg/kg and by
72 h post-dose for doses above 10 mg/kg (Fig. 3). Sphin-
gomyelin levels returned to baseline by 24 h post-dose for
doses up to 5 mg/kg, by 72 h post-dose for doses from 10
to 30 mg/kg and by 7 days post-dose for subjects dosed
with 45 mg/kg (data not shown).
CER-001 caused dose-dependent elevations in total
plasma cholesterol (data not shown) as well as total and
unesterified cholesterol in the HDL fraction (Fig. 4a, b),
suggesting increased reverse lipid transport. Mobilisation
in the HDL fraction of unesterified cholesterol was seen
with a CER-001 dose as low as 2 mg/kg (mean 23%
increase from baseline) and increased with dose. Triglyc-
eride levels were transiently increased above levels seen
with placebo at doses of 15 mg/kg and above (data not

























C - Cholesterol ester

















Fig. 1 Increase in mean plasma
a total cholesterol,
b unesterified (free) cholesterol
and c esterified cholesterol
following intravenous infusion
of CER-001 into fasted rabbits.
CER-001 doses: 0 (squares), 2.5
(triangles), 5 (inverted
triangles), 10 (diamonds) or 20
(circles) mg/kg. There were
three animals per group. At
various times post-dose, plasma
total, unesterified and esterified
cholesterol levels were
measured. Baseline values were
subtracted to determine the
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doses, was not associated with significant elevation of liver
enzymes (Fig. 5). These data support the further evaluation
of CER-001 at a wide range of doses as potential therapy
for patients with atherosclerotic diseases.
All doses of CER-001 were safe and well tolerated, with
an AE profile similar to that observed with placebo
(Table 3). Four of 32 subjects (12.5%) had an AE fol-
lowing a single dose of CER-001 vs. 3 of 32 subjects
(9.4%) who had an AE following a single dose of placebo.
No subjects had AEs considered by the investigator to be at
least possibly related to the study drug and there did not
appear to be any dose-related trends in the occurrence or
type of AEs. There were no deaths, serious AEs or AEs that
led to withdrawal from the study or study treatment.
The effects of CER-001 on clinical chemistry, haema-
tology and coagulation parameters were comparable to
placebo, including the effects on liver enzymes. No adverse
effects of CER-001 on electrocardiograms were observed.
Table 1 Mean change in plasma total cholesterol, unesterified (free)
cholesterol and esterified cholesterol following intravenous infusion
of CER-001 into fasted rabbits allowed free access to food after 8 h
Measure/time (h) CER-001 (mg/kg)
Placebo 2.5 5.0 10.0 20.0
Total cholesterol
30 -0.286 -0.137 0.047 -0.029 0.046
34 -0.274 -0.149 0.017 -0.173 -0.090
Free cholesterol
30 -0.038 -0.007 0.039 0.086 0.068
34 -0.049 -0.023 0.006 -0.005 -0.001
Cholesterol ester
30 -0.248 -0.130 0.008 -0.115 -0.022
34 -0.225 -0.126 0.011 -0.168 -0.089
Baseline values were subtracted to determine the change in choles-
terol levels. Baseline total cholesterol: 0.41–1.08 g/L; unesterified




































































































Fig. 2 Effect of increasing doses of CER-001 and HDL3 on mean
(±standard error of the mean) atherosclerotic plaque progression in
ligatured carotid of apoE-/- mice. The left carotid of apoE-/- mice
(n = 12) was ligatured, fed with a high-cholesterol diet and treated
(retro-orbital injection) every second day with CER-001 or HDL3
(eight infusions). The carotids were lipid extracted and cholesterol
levels were determined by high-performance liquid chromatography.
a Unesterified cholesterol. b Total cholesterol. c Protein level of
ABCA1 measured in the ligatured carotids using western blot
analysis. *p\ 0.05; **p\ 0.01; ***p\ 0.001; ****p\ 0.0001 vs.
baseline. ABCA1 ATP-binding cassette transporter 1, apoE
apolipoprotein E
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No antibodies to ApoA-I were detected following single-
dose administration of CER-001.
4 Discussion
4.1 Preclinical Findings
Dose-dependent increases in serum cholesterol levels
occurred at all doses of CER-001 tested in the preclinical
pharmacology and toxicity studies, which is the expected
pharmacological effect of CER-001 administration. CER-
001 at 20 mg/kg was considered the no adverse-effect level.
Minimal adverse effects observed at doses of 50 and
100 mg/kg were considered secondary to increased choles-
terol levels following CER-001 administration and were
completely reversible during the treatment-free period. In a
cardiovascular and respiratory primate safety study, CER-
001 at doses up to 100 mg/kg was devoid of any adverse
effects on blood pressure, heart rate and body temperature.
A small but statistically significant increase in heart rate at
the 100-mg/kg dose was considered loss of diurnal rhythm
(data not shown). In the first single-dose clinical study, the
starting dose was 0.25 mg/kg, as this was 1/80th of the safe
dose (20 mg/kg) as established in the 4-week multiple-dose
animal studies dosed every second day.
4.2 Phase I Single Rising-Dose Clinical Study
Findings
In this phase I clinical study, following administration of
CER-001, plasma ApoA-I levels increased in a dose-re-
lated manner, returning to baseline by 24 h post-dose for
doses up to 10 mg/kg and remaining in circulation longer
than 72 h post-dose for doses C10 mg/kg, suggesting a
longer residence time of CER-001 in plasma. The admin-
istration of CER-001 caused elevations in plasma choles-
terol, as well as total and unesterified cholesterol in the
HDL fraction, suggesting increased reverse lipid transport.
The mobilisation of unesterified cholesterol in the HDL
fraction was seen with CER-001 doses as low as 2 mg/kg,
indicating efficacy at very low doses and supporting the
evaluation of a wide range of doses as potential therapy for
patients with atherosclerotic disease.
Table 2 Subjects’ baseline demographics in the phase I study by CER-001 dose
CER-001 (mg/kg)
0.25 (n = 4) 0.75 (n = 4) 2 (n = 4) 5 (n = 4) 10 (n = 4) 15 (n = 4) 30 (n = 4) 45 (n = 4)
Age, years
Mean (SD) 28.8 (8.4) 40.8 (7.6) 30.0 (8.8) 29.0 (8.4) 32.8 (11.2) 33.8 (4.0) 35.0 (12.1) 39.3 (11.9)
Median (range) 26.0 (22–41) 39.5 (33–51) 28.5 (22–41) 27.0 (22–40) 31.0 (21–48) 35.0 (28–37) 38.5 (18–45) 41.0 (24–51)









































Fig. 3 Mean apoA-I levels
(adjusted for pre-dose level) in
healthy subjects following
administration of placebo or
CER-001. apoA-
I apolipoprotein A-I
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CER-001 was well tolerated at all doses in all subjects
with an adverse-event profile similar to that observed with
placebo. CER-001 did not appear to affect clinical chem-
istry, haematology or coagulation parameters differently
from placebo. No adverse effects of CER-001 were
observed on electrocardiograms and no antibodies to
ApoA-I were detected following single-dose administration
of CER-001.
Overall, this article presents a series of preclinical and
human volunteer data in which the initial preclinical find-
ings with CER-001 have allowed accurate estimation of the
human clinical dose level. The subsequent effectiveness
observed with CER-001 in patients parallels that reported
during the early development of the compound. At dose
levels C2 mg/kg, CER-001 increased cholesterol mobili-
sation into the HDL fraction (up to sevenfold) and signif-
icant HDL increases were demonstrated. No drug-related
AEs were observed at any dose. Importantly, there were no
increases in hepatic enzymes despite a maximum choles-
terol mobilisation ten times greater than that observed with
prior HDL mimetics.
Clinical effectiveness of CER-001 has now been
reported in phase II studies in patients with acute coronary
syndrome, with higher doses being less effective than
lower doses [7]—this reflects findings in the preclinical
studies reported here and elsewhere [13] and can be
explained by the down-regulation of ABCA1. Despite this
concern of a down-regulation at higher doses, the clinical
effectiveness of CER-001 has also been observed in plaque
regression in patients with genetic dyslipidaemia or acute
coronary syndrome [8–10].
HDL-directed therapy is a strategy intended to supple-
ment LDL-cholesterol-lowering treatment. Proof of con-
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Fig. 4 Mean a total and
b unesterified (free) cholesterol
mobilisation (expressed as mean
percentage change from pre-
dose level) in the high-density
lipoprotein fraction of human
plasma from healthy subjects
following administration of
placebo or CER-001
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transport pathway and for regression of atherosclerotic
burden in patients across the spectrum of defects in
cholesterol homeostasis has now been demonstrated. This
offers considerable optimism that CER-001 may address
the residual risk of cardiovascular events that remains after
maximum clinical benefit has been achieved using LDL-
cholesterol-lowering therapies; the results of further studies
involving CER-001 are eagerly awaited.
5 Conclusion
Preclinical pharmacological studies have shown that CER-
001 produces dose-dependent increases in serum choles-
terol levels, while the phase I study has demonstrated it to
be well tolerated when administered to humans as a single
dose up to 45 mg/kg and that it mobilises and eliminates
cholesterol via reverse lipid transport.
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Fig. 5 Individual 24-h ALT values vs. cholesterol mobilisation in healthy subjects following administration of placebo or CER-001. ALT alanine
aminotransferase






















No. of AEs 0 1 0 0 0 1 1 1 4 4
No. of subjects with an AE (%) 0 1 (25) 0 0 0 1 (25) 1 (25) 1 (25) 4 (13) 3 (9)
Abdominal pain 0 0 0 0 0 0 1 (25) 0 1 (3) 0
Diarrhoea 0 0 0 0 0 1 (25) 0 0 1 (3) 0
Hordeolum 0 1 (25) 0 0 0 0 0 1 (3) 0
Nasopharyngitis 0 0 0 0 0 0 0 0 0 1 (3)
Limb injury 0 0 0 0 0 0 0 1 (25) 1 (3) 0
Presyncope 0 0 0 0 0 0 0 0 0 1 (3)
Cough 0 0 0 0 0 0 0 0 0 1 (3)
Oropharyngeal pain 0 0 0 0 0 0 0 0 0 1 (3)
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and good laboratory practice guidelines for the care of the laboratory
animals were followed.
Consent to participate All participants provided written informed
consent prior to entering the study.
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